13F Holdings
中文EN

CNTX Context Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1842952 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-66.0%
TTM EPS YoY-91.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-84.3%
ROA-75.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets15.1%
Debt / equity0.00x
Current ratio6.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$31.86M$22.70M$17.78M$7.09M$3.81M
SG&A expense$7.85M$7.22M$7.29M$7.79M$3.63M
Operating income-$39.70M-$29.92M-$25.07M-$15.38M-$10.53M
Interest expense————$64,240
Income tax$0$0$0$0$0
Net income-$36.12M-$26.73M-$23.96M-$14.84M-$10.46M
EBITDA-$39.69M-$29.91M-$25.06M-$15.37M-$10.53M
EPS (basic)-0.38-0.46-1.50-0.93-3.69
EPS (diluted)-0.38-0.46-1.50-0.93-3.69
Weighted avg. shares (diluted)95.19M58.42M15.97M15.97M2.83M
Banking
Net interest income——$1.16M$547,268-$64,240
Balance sheet
Cash & equivalents$66.00M$94.43M$14.45M$35.50M$49.69M
Current assets$68.35M$97.90M$16.05M$37.85M$51.26M
PP&E, net$29,656$11,959$15,524$27,568$0
Total assets$68.49M$98.13M$16.06M$37.97M$51.31M
Current liabilities$8.02M$2.75M$4.19M$3.21M$3.03M
Total liabilities$8.02M$2.86M$4.19M$3.21M$3.03M
Shareholders' equity$60.47M$95.27M$11.87M$34.76M$48.27M
Shares outstanding91.88M89.70M15.97M15.97M15.97M
Cash flow statement
Operating cash flow-$26.39M-$14.56M-$21.05M-$13.55M-$8.80M
Capital expenditure$33,948$7,316$0$36,836$0
Free cash flow-$26.42M-$14.56M-$21.05M-$13.59M-$8.80M
Investing cash flow-$2.03M-$14.76M$0-$536,836-$250,000
Financing cash flow-$15,268$109.29M$0-$102,071$58.39M
Depreciation & amortization$16,251$10,881$12,044$9,268$0
Stock-based compensation$1.33M$841,867$1.08M$976,440$511,079

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.